1. A survey of architectures and scenarios in satellite‐based wireless sensor networks: system design aspects. (27th November 2012) Authors: Celandroni, N.; Ferro, E.; Gotta, A.; Oligeri, G.; Roseti, C.; Luglio, M.; Bisio, I.; Cello, M.; Davoli, F.; Panagopoulos, A. D.; Poulakis, M.; Vassaki, S.; De Cola, T.; Marchitti, M. A.; Hu, Y. F.; Pillai, P.; Verma, S.; Xu, K.; Acar, G. Journal: International journal of satellite communications and networking Issue: Volume 31:Number 1(2013:Jan./Feb.) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Epidemiology, clinical presentation and outcomes of venous thromboembolism: A single center experience over 6 years period. Issue 1 (July 2015) Authors: Al-Thani, H.; El-Menyar, A.; A.S. kilyanni, ; Pillai, P.; John, S.; Paul, J.; Asim, M. Journal: Atherosclerosis Issue: Volume 241:Issue 1(2015) Page Start: e227 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Epidemiology, clinical presentation and outcomes of venous thromboembolism: A single center experience over 6 years period. Issue 1 (July 2015) Authors: Al-Thani, H.; El-Menyar, A.; A.S. kilyanni; Pillai, P.; John, S.; Paul, J.; Asim, M. Journal: Atherosclerosis Issue: Volume 241:Issue 1(2015) Page Start: e227 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P1086: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN ANTI–PD-1–NAIVE PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: AN OPEN-LABEL PHASE 1/2 STUDY. (23rd June 2022) Authors: Gregory, G.; Timmerman, J.; Lavie, D.; Borchmann, P.; Herrera, A. F.; Minuk, L.; Vucinic, V.; Armand, P.; Avigdor, A.; Gasiorowski, R.; Herishanu, Y.; Keane, C.; Kuruvilla, J.; Palcza, J.; Pillai, P.; Marinello, P.; Johnson, N. A. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 976 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P1087: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA WHO PROGRESSED AFTER ANTI–PD-1 THERAPY: AN OPEN-LABEL PHASE 1/2 STUDY. (23rd June 2022) Authors: Herrera, A. F.; Lavie, D.; Johnson, N. A.; Avigdor, A.; Borchmann, P.; Andreadis, C.; Bazargan, A.; Gregory, G.; Keane, C.; Inna, T.; Vucinic, V.; Zinzani, P. L.; Zhang, H.; Pillai, P.; Marinello, P.; Timmerman, J. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 977 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. PHASE 2 KEYNOTE-667 STUDY OF PEMBROLIZUMAB (PEMBRO) IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED CLASSICAL HODGKIN LYMPHOMA (Chl) AND SLOW EARLY RESPONSE (SER) TO FRONTLINE CHEMOTHERAPY (CHEMO). (October 2022) Authors: Vinti, L.; Daw, Stephen; Alvarez, C.; Fagioli, F.; Beishuizen, A.; Michel, G.; Moleti, M.; Cepelova, M.; Thorwarth, A.; Rigaud, C.; de Sabando, D.; Parker, J.; Zhu, Y.; Pillai, P.; Nahar, A.; Mauz-Koerholz, C. Journal: Leukemia research Issue: Volume 121(2022)Supplement Page Start: S33 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. S204: PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED CLASSICAL HODGKIN LYMPHOMA WITH SLOW EARLY RESPONSE TO FRONTLINE CHEMOTHERAPY: THE PHASE 2, OPEN-LABEL, KEYNOTE-667 STUDY. (23rd June 2022) Authors: Vinti, L.; Daw, S.; Sabado Alvarez, C.; Fagioli, F.; Beishuizen, A.; Michel, G.; Moleti, M. L.; Cepelova, M.; Thorwarth, A.; Rigaud, C.; Plaza Lopez de Sabando, D.; Landman Parker, J.; Zhu, Y.; Pillai, P.; Nahar, A.; Mauz-Koerholz, C. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 105 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗